A study on the cost-effectiveness on the pharmacologic treatments for age-related macular degeneration

• Grant number: 10/15451-0
• Support Opportunities: Regular Research Grants
• Start date: July 01, 2011
• End date: March 31, 2014
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Michel Eid Farah
• Grantee: Michel Eid Farah
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• Associated researchers: Eduardo Büchele Rodrigues ; Mauricio Maia ; Octaviano Magalhães Junior ; Renata Portella Nunes

Abstract

To study the efficacy and cost-effectiveness of treatments with ranibizumab and bevacizumab against exudative age-related macular degeneration (AMD). Methods: A prospective randomized clinical trial to compare the efficacy of ranibizumab and bevacizumab for therapy against exudative AMD. Forty-five patients with exudative AMD will be allocated in three groups for an intensive three month therapy: monthly 0.5mg ranibizumab injection, monthly 1.25mg bevacizumab injection, and a third group will receive every-two-weeks 1.25mg bevacizumab injection. Afterwards, the patients will be followed monthly with visual acuity based on the ETDRS, optical coherence tomography, fluorescein angiography, eletrophysiology, and microperimetry for one year. The patients that present increase in 100micra or more or loss of at least one line of vision will receive additional injections. Patients belonging to the third group will be followed on a every-two-weeks basis. One sub-analysis of the study will be evaluation of the cost-effectiveness of the two drugs available for therapy of age-related macular degeneration. Results: Three groups of patients will be evaluated in regard to effficacy and cost-effectiveness of the therapy. Conclusions: The research group aims to elucidate if the efficacy of bevacizumab is comparable to ranibizumab in the therapy of exudative AMD, since bevacizumab can be 10 to 30 times cheaper than ranibizumab. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

RENATA PORTELLA NUNES; FLÁVIO EDUARDO HIRAI; EDUARDO BUCHELLE RODRIGUES; MICHEL EID FARAH. Estudo de custo-efetividade de tratamentos para a degeneração macular relacionada à idade: uma perspectiva brasileira. Arquivos Brasileiros de Oftalmologia, v. 83, n. 1, p. 48-54, 2020-02-27. (10/15451-0)

NUNES, RENATA PORTELLA; HIRAI, FLAVIO EDUARDO; BARROSO, LETICIA FERNANDES; BADARO, EMMERSON; NOVAIS, EDUARDO; RODRIGUES, EDUARDO BUCHELE; MAIA, MAURICIO; MAGALHAES, JR., OCTAVIANO; FARAH, MICHEL EID. Efetividade de tratamentos anti-VEGF mensais e quinzenais para a degeneração macular relacionada à idade. Arquivos Brasileiros de Oftalmologia, v. 82, n. 3, p. 225-232, MAY-JUN 2019. (10/15451-0)